Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- Resource Type
- Source
- Diabetes, Obesity and Metabolism. 16:1016-1027
- Subject
Blood Glucose Male medicine.medical_specialty Endocrinology, Diabetes and Metabolism Urinary system Urology Renal function Blood Pressure Thiophenes Placebo Drug Administration Schedule Diabetic nephropathy chemistry.chemical_compound Endocrinology Double-Blind Method Glucosides Sodium-Glucose Transporter 2 Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Diabetic Nephropathies Canagliflozin Renal Insufficiency, Chronic Sodium-Glucose Transporter 2 Inhibitors Aged Creatinine business.industry Body Weight medicine.disease Treatment Outcome Blood pressure Diabetes Mellitus, Type 2 chemistry Disease Progression Female business Glomerular Filtration Rate Kidney disease medicine.drug - Language
- ISSN
- 1462-8902